The efficacy of echinacea compound herbal tea preparation on the severity and duration of upper respiratory and flu symptoms: a randomized, double-blind placebo-controlled study. The efficacy of Echinacea compound herbal tea preparation on the severity and duration of upper respiratory and flu symptoms: a randomized, double blind, placebo-controlled study. Please also consult your physician for a complete list of indications, warnings, precautions, adverse events, clinical results, and other important medical information.

A systematic review study reported that echinacea supplementations may help increase the levels of anti-inflammatory cytokine i X Small protein cells that play a role in controlling the activity of the immune system and blood cells IL-10 and pro-inflammatory cytokine IFN. Next, we investigated whether prevention of RTI episodes with EFJ would result in fewer RTI complications. Control tablets contained 50 mg vitamin C (20 mg ascorbic acid and 36 mg calcium ascorbate) and the same amount of natural orange flavor like verum for masking. Archaeologists have found evidence that Native Americans may have used echinacea for more than 400 years to treat infections and wounds, and as a general "cure-all. One Echinaforce Junior ® (EFJ) tablet contains 400 mg of hydro-ethanolic extract (65% v/ v) of freshly harvested Echinacea purpurea.A total of 45 and 216 days of antibiotic therapy were reported in the two groups, respectively (reduction of 80. We’ve made it simple for you by providing an easy-to-use bulb to dispense the suggested serving size. In vitro and in vivo immune stimulating effects of a new standardized Echinacea angustifolia root extract (Polinacea). Besides, the topical use of Echinacea is also known to treat wounds, ulcers, cold sores, insect bites, eczema, and allergies (13).

Development of a symptom score for clinical studies to identify children with a documented viral upper respiratory tract infect. Its effect in preventing enveloped virus infections (including RSV) as well as a prior study showing efficacy of Echinacea in children 1–5 years of age [ 30] suggests the use in younger children as well. Adrian L Lopresti and Stephen J Smith; (2021); An investigation into the anxiety-relieving and mood-enhancing effects of Echinacea angustifolia (EP107™): A randomised double-blind placebo-controlled study. The NHS suggests that the intake of echinacea may interfere with the functioning of the kidneys (18). Benefits included a specific prevention of enveloped virus infections, including RSV and in particular a marked reduction of influenza virus infections.In vitro inhibition of cyclooxygenase and 5-lipoxygenase by alkamides from Echinacea and Achillea species. of parents and investigators judged the tolerability of EFJ as “ (very-) good”, similar to the control group with 95. We recommend that you read labels, warnings and directions of all products before use and not rely solely on the information provided by Evolution Organics. Hence, the present study investigated the efficacy of Echinacea for the prevention of viral RTIs, for the prevention of secondary bacterial complications of these viral RTIs and for reducing rates of antibiotic prescriptions in children. The use of echinacea as a dietary supplement or herbal medicine isn’t well-regulated, as dietary supplements and herbal medicines do not undergo the US FDA’s safety regulation checks.

Anyone who has concerns should speak to their doctor, pharmacist or qualified healthcare practitioner. A sensitivity analysis excluded children whose physicians and/or parents correctly guessed their allocated treatment and showed that above results remained robust, positive and significant. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD.EFJ tablets were packaged into dark brown glass bottles containing either 40 or 60 tablets per bottle. You should contact the manufacturer directly for clarification as to product labeling and packaging details and recommended use. The safety population comprised all subjects having administered at least one dose of IMP, the intention-to-treat (ITT) population included all subjects reporting at least one assessment of efficacy and/or safety and finally the per-protocol (PP) population included patients from the ITT population with 80% compliance in terms of IMP intake, no premature study termination and complying with in- and exclusion criteria. As a consequence, 67% of general practitioners continued prescribing antibiotics for RTIs, with the highest prevalence (90%) for chest infections, 80% for ear infections and 60% for a sore throat [ 13].